brinsupri insmed - Search News

News

Insmed’s lung disease drug approved in U.S.

Insmed gains US approval of lung disease drug forecast to be blockbuster

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not caused by cystic fibrosis.

Reuters on MSN · 3d

US FDA approves Insmed's drug as first treatment for a chronic lung disease

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition.

Pharmaceutical Technology on M… · 2d

Insmed wins FDA approval for future blockbuster Brinsupri

Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed dipeptidyl peptidase 1 (DPP1) inhibitor and the first therapy for non-cystic fibrosis bronchiectasis (NCFB) approved by the US Food and Drug Administration (FDA).

Stocktwits on MSN2d

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...

PharmExec3d

FDA Approves Insmed’s Brinsupri as First Treatment for Non-Cystic Fibrosis Bronchiectasis

Brinsupri is a first-in-class DPP1 inhibitor that has been found to inhibit activation of neutrophil enzymes that drive chronic airway inflammation in non-cystic fibrosis bronchiectasis.

Fierce Pharma3d

Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor

With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...

PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

Asianet Newsable on MSN2d

Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic

Insmed shares surged after U.S. regulators approved Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis.

TipRanks on MSN3d

Show inaccessible results

News

Insmed’s lung disease drug approved in U.S.

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week

FDA Approves Insmed’s Brinsupri as First Treatment for Non-Cystic Fibrosis Bronchiectasis

Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor

PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic

Brinsupri approval sets stage for next leg of Insmed growth, says BofA

VytlOne Announces New Partnership with Insmed

Insmed price target raised to $138 from $120 at RBC Capital

Related topics